<DOC>
	<DOCNO>NCT02588235</DOCNO>
	<brief_summary>After successful coronary angiography OCT examination , patient TCFAs non-culprit , mild-to-moderate stenotic lesion enrol . Then , randomly assign 1:1 ratio receive either atorvastatin ( 20 mg/day ) alone atorvastatin ( 20 mg/day）plus ezetimibe（10 mg/day）by envelope method . Angiographic OCT follow-up schedule target vessel 12 month .</brief_summary>
	<brief_title>Ezetimibe Atorvastatin Therapy TCFA</brief_title>
	<detailed_description>This prospective , randomize , control , open-label , single-center study evaluate effect ezetimibe add atorvastatin coronary thin-cap fibroatheroma ( TCFA ) . After successful coronary angiography OCT examination , patient TCFAs non-culprit , mild-to-moderate stenotic lesion enrol . Then , randomly assign 1:1 ratio receive either atorvastatin ( 20 mg/day ) alone atorvastatin ( 20 mg/day）plus ezetimibe（10 mg/day）by envelope method . Angiographic OCT follow-up schedule target vessel 12 months.The primary efficacy endpoint change minimum fibrous cap thickness measure OCT baseline follow-up.The secondary endpoint include absolute percent change lipid , glycemic , inflammatory profile . Then , change indicator compare respectively diabetic non-diabetic patient .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>1.stable angina acute coronary syndrome 2.1880 year old 3.hypercholesterolemia : total cholesterol level &gt; 220 mg/dl ( 5.7mmol/L ) and/or LDLC level &gt; 140 mg/dl ( 3.6mmol/L ) , previously receive statin therapy 4. target vessel OCT interrogation undergone angioplasty angiographic diameter stenosis 25 % 75 % 5.There TCFAs nonculprit , mildtomoderate stenotic lesion 1. administration lipidlowering drug statins enrollment 2. significant stenotic lesion coronary vessel 3. severe congestive heart failure ( New York Heart Association class IV ) , leave ventricular ejection fraction＜35 % 4. 3 time upper limit normal ( ULN ) creatine kinase ( CK ) transaminase level enrollment relation myocardial infarction 5. renal failure ( serum creatinine＞2.0 mg/dL） 6. hypersensitivity xray contrast medium , statin，clopidogrel ezetimibe 7 . Others : terminal stage cancer , positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>